APRINOIA Therapeutics
Boston · Founded 2015
About APRINOIA Therapeutics
APRINOIA is a late-stage biotechnology company committed to protecting patients' brain health and changing outcomes of neurodegenerative diseases through first-in-class and best-in-class diagnostic tools and novel therapies. The company aims to bring precision medicine to neuroscience by identifying and targeting the protein aggregates of tau, alpha-synuclein and other proteins that play a critical role in the pathogenesis of many neurodegenerative diseases, such as Alzheimer's and Parkinson's Diseases. The company currently has operations in Hong Kong, Suzhou, Shanghai, Tokyo, and Boston.
Company Facts
- Founded: 2015
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $61.9M
- Last round: Series Unknown (Sep 2023)
- Website: http://www.aprinoia.com/
- Phone: +1-617-225-4415
Industries & Categories
Biotechnology, Health Diagnostics, Medical, Neuroscience, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/aprinoia-therapeutics-166100 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.